Full professor Erasmus School of Health Policy & Management Health Technology Assessment (HTA)
- Location
- Burg. Oudlaan 50, Rotterdam
- Room
- J8-35
- uyl@eshpm.eur.nl
‹ Back to overview
Profile
Carin A. Uyl-de Groot studied Health Care Policy and Management at the Erasmus University Rotterdam. From March 1990 onwards she is working at the institute for Medical Technology Assessment/Department of Health Care Policy and Management at the Erasmus Medical Centre Rotterdam. Her research activities are mainly focused on cost-effectiveness analyses of cancer treatments. Quality of life studies are an integral part of these studies. From 1994 she is program leader of cancer studies. Her main interest consists of diagnostics and therapeutic technologies, economic studies linked to clinical studies, modelling studies, cost studies, quality of life studies, methodological issues and implementation studies particularly in the cancer field. She got her PhD in 1995. Since March 2000 she is director of the institute for Medical Technology Assessment. Since November 2005 she has been appointed professor of health technology assessment at the VU University Medical Center in Amsterdam.
- Martijn J.H.G. Simons, Carin A. Uyl-de Groot, Valesca P. Retèl, Joanne M. Mankor, Bram L.T. Ramaekers, Manuela A. Joore & Wim H. van Harten (2022) - Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer - Value in Health - doi: 10.1016/j.jval.2022.07.006 - [link]
- Yi Hsuan Chen, Dominique Molenaar, Carin A. Uyl-De Groot, Marco van Vulpen & Hedwig M. Blommestein (2022) - Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review - Cancers, 14 (10) - doi: 10.3390/cancers14102444 - [link]
- Peter Cram, Laura A Hatfield, Pieter Bakx, Amitava Banerjee, Christina Fu, Michal Gordon, Renaud Heine, Nicole Huang, Dennis Ko, Lisa M Lix, Victor Novack, Laura Pasea, Feng Qiu, Therese A Stukel, Carin de Groot, Lin Yan & Bruce Landon (2022) - Variation in revascularisation use and outcomes of patients in hospital with acute myocardial infarction across six high income countries: cross sectional cohort study - The BMJ, 377 - doi: 10.1136/bmj-2021-069164 - [link]
- Tobias B. Polak, David G.J. Cucchi, Joost van Rosmalen & Carin A. Uyl-de Groot (2022) - The DRUG Access Protocol: access inequality and European harmonisation - The Lancet Oncology, 23 (5), e202 - doi: 10.1016/S1470-2045(22)00098-5 - [link]
- Aniek Dane, Soedaba Ashraf, James Timmis, Monique Bos, Carin Uyl-de Groot & P. Hugo M. van der Kuy (2022) - Barriers to patient enrolment in phase III cancer clinical trials: interviews with clinicians and pharmaceutical industry representatives - BMJ Open, 12 (2) - doi: 10.1136/bmjopen-2021-055165 - [link]
- Tobias Polak, David G.J. Cucchi, CA (Carin) Uyl - de Groot & Joost van Rosmalen (2022) - Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals - BMJ Open, 12 (1) - doi: 10.1136/bmjopen-2021-052186 - [link]
- C. Louwrens Braal, Anne Kleijburg, Agnes Jager, Stijn L.W. Koolen, Ron H.J. Mathijssen, Isaac Corro Ramos, Pim Wetzelaer & Carin A. Uyl-de Groot (2022) - Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial - Clinical Drug Investigation, 42 (2), 163-175 - doi: 10.1007/s40261-021-01114-6 - [link]
- Wing H. Tong & Carin A. Uyl-De Groot (2021) - Comment on: “Premedication prior to PEG-asparaginase is cost effective in pediatric patients with acute lymphoblastic leukemia” - Pediatric Blood and Cancer, 69 (4) - doi: 10.1002/pbc.29474 - [link]
- Frederick W. Thielen, Marie José Kersten, Pim Kuizenga, Mels Hoogendoorn, Eduardus F.M. Posthuma, Wendy B.C. Stevens, Carin A Uyl-de Groot & Hedwig M. Blommestein (2021) - Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view - Expert Review of Anticancer Therapy, 21 (12), 1411-1422 - doi: 10.1080/14737140.2021.1971520 - [link]
- Lytske Bakker, Jos Aarts, Carin Uyl-de Groot & Ken Redekop (2021) - How can we discover the most valuable types of big data and artificial intelligence-based solutions? A methodology for the efficient development of the underlying analytics that improve care - BMC Medical Informatics and Decision Making, 21 (1) - doi: 10.1186/s12911-021-01682-9 - [link]
- Carin Uyl - de Groot, Ken Redekop, Amir Ansaripour, K. Zendehdel, N. Tadayon & F. Sadeghi (2016) - Use of data-mining to perform a real world cost analysis of HER2-positive breast cancer in Iran
Cie Beoordeling Oncologische Middelen
- Begindatum goedkeuring
- juli 2022
- Einddatum goedkeuring
- juli 2025
- Plaats
- UTRECHT
Gezondheidsraad
- Begindatum goedkeuring
- juli 2022
- Einddatum goedkeuring
- juli 2025
- Plaats
- DEN HAAG
bestuurslid CPO, Erasmus Medisch Centrum
- Begindatum goedkeuring
- juli 2022
- Einddatum goedkeuring
- juli 2025
- Plaats
- ONBEKEND
Master Thesis HE
- Year
- 2022
- Year Level
- master, master
- Course Code
- GW4592M
Master Thesis HEPL
- Level
- master
- Year
- 2022
- Year Level
- master
- Course Code
- GW4555M
